About luspaterc ept + vial
Erythroid maturation agent
Used for
- Treats anemia in certain adults with beta thalassemia who need regular transfusions.
- Treats anemia in adults with lower-risk myelodysplastic syndromes, in specific clinical situations.
Usual adult dose
Starting dose is usually 1 mg/kg by injection under the skin every 3 weeks; doses may be adjusted by response and indication.
Common side effects
- Tiredness, headache, dizziness, or muscle and joint pain
- Nausea, diarrhea, or abdominal pain
- High blood pressure
- Injection-site reactions
Important warnings
- May cause high blood pressure; monitoring is recommended.
- Can increase blood clots, especially in people with beta thalassemia.
- May cause harm to an unborn baby; effective contraception is advised during treatment and for three months afterward.
- Not a substitute for transfusions when transfusions are needed.
Pregnancy
May harm an unborn baby. Human pregnancy information is limited; contraception is advised during treatment and for three months after the last dose.
Breastfeeding
It is not known whether luspatercept passes into breast milk. Breastfeeding is not recommended during treatment and for three months after the last dose.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.